AMENDMENTS TO THE CLAIMS

Claim Listing

1. (original) A compound of the general formula I or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof



(I)

wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR'_3, SOR', SO_2R', C(=O)R', C(=O)OR', C(=O)NR', substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl;

the group R' is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and

the group R" is selected from the group consisting of H, OH, OR', OCOR', SH, SR', SOR', SO_2R', NO_2, NH_2, NHR', $N(R')_2$, NHCOR', $N(COR')_2$, $NHSO_2R'$, CN, halogen, C(=O)H, C(=O)R', CO_2H, CO_2R', CH_2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substituted, or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic;

with the proviso that the compound is not compound 1, 3 or 4 of US 5,514,708.

2. (currently amended) A compound according to claim 1, with the following stereochemistry



3. (original) A compound according to claim 1, wherein R" is CH_2OH

5

which may exist as a mixture of the ketone isomer and the hemiketal isomer, or as one of the two isomeric forms.

4. (currently amended) A compound according to claim 3, with the following stereochemistry

5. (currently amended) A compound according to claim 4, with the following stereochemistry

6. (currently amended) A compound according to claim 4, with the following stereochemistry

7. (original) A compound according to claim 1 or 2, wherein R" is a substituted or unsubstituted alkylidene.

8. (currently amended) A compound according to ~~any of claims 3 to 6~~ claim 3, wherein at least one of the R substituents is C(=O)R'.

9. (currently amended) A compound according to claim 8, which is of formula **47**

10. (original) A compound according to claim 1, wherein at least one of the R substituents is not hydrogen.

11. (original) A compound according to claim 10, wherein each group R that is not hydrogen is a protecting group, which may be the same or different.

12. (original) A compound according to claim 11, which is of formula



where R^1, R^2, R^6 and R^7 are hydroxy protecting groups.

13. (currently amended) A compound according to claim 12, which is of the formula **19**:



where R^1, R^2, R^6 and R^7 are hydroxy protecting groups.

14. (original) A compound according to claim 12, which is of the formula **30**:



where R^1, R^2, R^6 and R^7 are hydroxy protecting groups.

15. (currently amended) A compound according to ~~any of claims 12-14~~ claim 12, wherein R^1, R^2, R^6 and R^7 are the same protecting group.

16. (currently amended) A compound according to ~~any of claims 12-15~~ claim 12, wherein R^1, R^2, R^6 and R^7 are chosen from TBS ($tBuMe_2Si$-), TBDPS ($tBuPh_2Si$-), TES (Et_3Si-), MOM (CH_3OCH_2-), MEM ($CH_3OCH_2CH_2OCH_2$-), SEM ($(CH_3)_3SiCH_2CH_2OCH_2$-) and Ac- (CH_3CO-).

17. (original) A compound according to claim 16, wherein R^1, R^2, R^6 and R^7 are chosen from TBS ($tBuMe_2Si$-) and TBDPS ($tBuPh_2Si$-).

18. (original) A compound according to claim 11, which is of formula



where R^1 is a hydroxy protecting group.

19. (currently amended) A compound according to claim 18, which is of the formula **20**:

20. (currently amended) A compound according to claim 11, which is formula **31**:

21. (currently amended) A compound according to ~~any of claims 11 to 20, wherein R^1~~ claim 11, wherein the protecting group is TBS ($tBuMe_2Si$-).

22. (currently amended) A pharmaceutical composition comprising a compound according to claim 1 ~~of formula I or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer or an intermediate of their synthesis thereof, as defined in any of claims 1 to 21~~, and a pharmaceutically acceptable carrier.

23. (currently amended) ~~The use of a compound of formula I or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, as defined in any of claims 1 to 21, in the preparation of a medicament for treating a tumour.~~ A method of preparing a medicament for treating a tumor comprising combining a compound according to claim 1 with a pharmaceutically acceptable carrier.

24. (currently amended) A method of treating a ~~tumour~~ tumor which comprises administering an effective amount of a compound according to claim 1 ~~of formula I or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof, as defined in any of claims 1 to 21~~.

25. (currently amended) A process for synthesis of a myriaporone compound of formula 5:

5

which may exist as a mixture of the ketone isomer and the hemiketal isomer, or as one of the two isomeric forms;

wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR'_3, SOR', SO_2R', C(=O)R', C(=O)OR', C(=O)NR', substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl, and wherein at least one group R is hydrogen;

and wherein the group R' is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups;

which comprises removing a protecting group from an intermediate compound of formula:



wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR'_3, SOR', SO_2R', C(=O)R', C(=O)OR', C(=O)NR', substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,

aryl, heteroaryl or aralkyl, and wherein the or each group R to become hydrogen in the compound 5 is in the intermediate compound a protecting group; and wherein the group R' is as defined.

26. (original) A process according to claim 25, wherein more than one group R in the intermediate compound is a protecting group.

27. (currently amended) A process according to claim 25, which comprises removing at least one protecting group from a compound of formula 19:





where R^1, R^2, R^6 and R^7 are hydroxy protecting groups.

28. (currently amended) A process according to claim 25, which comprises removing at least one protecting group from a compound of formula 30:





where R^1, R^2, R^6 and R^7 are hydroxy protecting groups.

29. (original) A process according to any of claims 25 to 28, wherein R^1, R^2, R^6 and R^7 are the same protecting group and are removed.

30. (currently amended) A process according to claim 25, which comprises removing a protecting group from a compound of formula 20:



where R^1 is a hydroxy protecting group.

31. (original) A process according to claim 25, which comprises removing a protecting group from a compound of formula 31:



where R^1 is a hydroxy protecting group.

32. (currently amended) A process for synthesis of a myriaporone compound of formula I:



(I)

wherein the substituent groups R and R" are as defined in claim 1;

which comprises derivatisation of a compound of formula 5:

which may exist as a mixture of the ketone isomer and the hemiketal isomer, or as one of the two isomeric forms; and wherein the substituent groups are as defined in claim 25.

33. (currently amended) A process according to claim 25 ~~any of claims 25 to 32~~, when carried out by the steps of Scheme 1 starting from compound 6





Scheme 1

where R^1, R^2, R^4, R^6 and R^7 are hydroxy protecting groups.

34. (currently amended) A process according to claim 25 ~~any of claims 25 to 32~~, when carried out by the steps of Scheme 2 starting from compound 6





23



24



25



26



27



28



29



Scheme 2

where R^1, R^2, R^4, R^6 and R^7 are hydroxy protecting groups.

35-49. (canceled)